About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1022 record(s)
Req # A-2020-001682
Adverse Drug Reactions (ADRs). Report numbers: E2B_03361270, E2B_03292659, E2B_03333792, E2B_03297856, E2B_03288214, E2B_03342866, E2B_03386949, E2B_03278465, E2B_03401712, E2B_03402109, E2B_03383022, E2B_03390637, E2B_03286279, E2B_03287731,…Organization: Health Canada
December 2021
Req # A-2020-001807
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-114477-391.Organization: Health Canada
December 2021
Req # A-2020-001892
Adverse Drug Reactions (ADRs) for Januvia. Report numbers: E2B_01476232, 000700596, 000700172, 000702831, E2B_00412992, 000706797. ADRs for Keytruda. Report numbers: 000696124, 000699458, 000699544.Organization: Health Canada
December 2021
Req # A-2021-000021
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116090-508.Organization: Health Canada
December 2021
Req # A-2021-000073
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_03706888, E2B_03703577, E2B_03690817, E2B_03650148, E2B_03703572, 000934984, 000934900. ADRs for Vyvanse. Report numbers: 000933539, 000934356, 000934242, 000933957. ADR for…Organization: Health Canada
December 2021
Req # A-2021-000177
Adverse Drug Reaction (ADR). Report number: E2B_03769938.Organization: Health Canada
December 2021
Req # A-2021-000187
Adverse Drug Reactions (ADRs). Report numbers: E2B_00767615, E2B_02625820, E2B_03239333, E2B_03294549, E2B_03344059, E2B_03353109, E2B_02247251, E2B_03317883, E2B_02625820, E2B_02676622.Organization: Health Canada
December 2021
Req # A-2021-000420
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075019-732.Organization: Health Canada
December 2021
Req # A-2021-000479
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116936-246.Organization: Health Canada
December 2021
Req # A-2021-000506
Adverse Drug Reaction (ADR) TERIFLUNOMIDE. Report number: E2B_03519847.Organization: Health Canada
December 2021